Publications by authors named "V C Giri"

Purpose: To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations.

Methods: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024.

View Article and Find Full Text PDF

Alternaria alternata, a common necrotrophic fungal pathogen, poses a significant threat to various crops, causing substantial yield losses and quality deterioration. In the present study, we explore the potential fungicidal properties of Peppermint Oil Nanoemulsion (PNE) against A. alternata and investigate its impact on the fungal phenotype.

View Article and Find Full Text PDF

Background: Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-engagement of Black males in PCA GT, limiting the benefit of precision therapy and tailored cancer screening despite longstanding awareness of these disparities.

View Article and Find Full Text PDF

A 14-day rat study with plasma metabolomics was conducted to evaluate the toxicity of Benzene. Wistar rats were orally administered Benzene daily at doses of 0, 300 and 1000 mg/kg bw. The study identified liver and kidneys as target organs of Benzene toxicity and found reductions in total white blood cells, absolute lymphocyte and eosinophil cell counts, and increased relative monocyte counts suggesting bone marrow as a target organ.

View Article and Find Full Text PDF
Article Synopsis
  • - Half of all BRCA1 and BRCA2 gene mutation carriers are male, yet their increased cancer risks—especially for prostate, pancreatic, and breast cancers—are often overlooked compared to females.
  • - Current research shows a growing number of FDA-approved targeted therapies for cancers linked to BRCA1/2 mutations, and there are new clinical trials that focus on male carriers, highlighting the need for better screening and risk-reduction options.
  • - Despite these advancements, fewer males are getting genetic testing compared to females, and healthcare providers need to prioritize offering these tests to men to improve early detection and treatment for male carriers.
View Article and Find Full Text PDF